Ticker AKRO – Akero Therapeutics – sales, description, marketcap – Tickerday.com

AKRO

Akero Therapeutics

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 1.18B; Volume: 128.21K; AvgVol 3m: 328.95K; Beta: –;

Cost estimate:

P/E: –; EPS: -1.79; EPS growth quarter/prev quarter: -112.00%;

EPS growth this year: 4.50%; EPS growth past 5 years: ;

EPS ttm: -2.09;

P/S: ; P/B: 7.79; P/Cashflow: 9.58; P/FCF: ;

Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -44.80%; ROE – return on equity: -48.00%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 9.51%; Insider Transactions:27.36%;

Institutional Ownership: 73.30%; Institutional Transactions: 1.07%;

Data update: 07.10.2020.